These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 31907738)
1. Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies. Doi T; Boku N; Onozawa Y; Takahashi K; Kawaguchi O; Ohtsu A Invest New Drugs; 2020 Oct; 38(5):1390-1399. PubMed ID: 31907738 [TBL] [Abstract][Full Text] [Related]
2. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA Oncology; 2016; 90(1):10-20. PubMed ID: 26492090 [TBL] [Abstract][Full Text] [Related]
3. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335 [TBL] [Abstract][Full Text] [Related]
4. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. Boku N; Muro K; Machida N; Hashigaki S; Kimura N; Suzuki M; Lechuga M; Miyata Y Invest New Drugs; 2014 Apr; 32(2):261-70. PubMed ID: 23665950 [TBL] [Abstract][Full Text] [Related]
5. Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies. Sunakawa Y; Takahashi K; Kawaguchi O; Yamamoto N Invest New Drugs; 2022 Oct; 40(5):1032-1041. PubMed ID: 35771301 [TBL] [Abstract][Full Text] [Related]
6. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Isambert N; Freyer G; Zanetta S; You B; Fumoleau P; Falandry C; Favier L; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Trillet-Lenoir V Clin Cancer Res; 2012 Mar; 18(6):1743-50. PubMed ID: 22261804 [TBL] [Abstract][Full Text] [Related]
7. A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. Diaz-Padilla I; Siu LL; San Pedro-Salcedo M; Razak AR; Colevas AD; Shepherd FA; Leighl NB; Neal JW; Thibault A; Liu L; Lisano J; Gao B; Lawson EB; Wakelee HA Br J Cancer; 2012 Aug; 107(4):604-11. PubMed ID: 22805331 [TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Tew WP; Gordon M; Murren J; Dupont J; Pezzulli S; Aghajanian C; Sabbatini P; Mendelson D; Schwartz L; Gettinger S; Psyrri A; Cedarbaum JM; Spriggs DR Clin Cancer Res; 2010 Jan; 16(1):358-66. PubMed ID: 20028764 [TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. Xu J; Li Y; Sun X; Zhang D; Liu R; Ziti-Ljajic S; Shi D; Xue F; Le Bail N; Xu R Invest New Drugs; 2017 Aug; 35(4):463-470. PubMed ID: 28102464 [TBL] [Abstract][Full Text] [Related]
12. A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors. Wang-Gillam A; Tew WP; Rothenberg ML; Dupont J; Cooper W; Sternas L; Buzenet G; Sosman JA; Spriggs DR; Lockhart AC Invest New Drugs; 2012 Oct; 30(5):1958-61. PubMed ID: 22002018 [TBL] [Abstract][Full Text] [Related]
13. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Van Cutsem E; Khayat D; Verslype C; Billemont B; Tejpar S; Meric JB; Soussan-Lazard K; Assadourian S; Cartot-Cotton S; Rixe O Eur J Cancer; 2013 Jan; 49(1):17-24. PubMed ID: 22921183 [TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours. Freyer G; Isambert N; You B; Zanetta S; Falandry C; Favier L; Trillet-Lenoir V; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Fumoleau P Br J Cancer; 2012 Aug; 107(4):598-603. PubMed ID: 22790797 [TBL] [Abstract][Full Text] [Related]
15. Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study. Kojima Y; Yoshie R; Kawamoto H; Shimo A; Uejima T; Iwatani T; Motoyoshi A; Kanemaki Y; Boku N; Tsugawa K Oncology; 2019; 96(6):309-317. PubMed ID: 30893699 [TBL] [Abstract][Full Text] [Related]
16. A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method. Morita S; Nakata B; Tsuji A; Mitachi Y; Shirasaka T; Saji S; Ohashi Y; Sakamoto J; Hirakawa K Jpn J Clin Oncol; 2007 Dec; 37(12):924-9. PubMed ID: 18211983 [TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391 [TBL] [Abstract][Full Text] [Related]
18. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer. Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558 [TBL] [Abstract][Full Text] [Related]
19. Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. Ikeda M; Shiina S; Nakachi K; Mitsunaga S; Shimizu S; Kojima Y; Ueno H; Morizane C; Kondo S; Sakamoto Y; Asaoka Y; Tateishi R; Koike K; Arioka H; Okusaka T Invest New Drugs; 2014 Oct; 32(5):928-36. PubMed ID: 24829073 [TBL] [Abstract][Full Text] [Related]
20. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Shin SJ; Jung M; Jeung HC; Kim HR; Rha SY; Roh JK; Chung HC; Ahn JB Invest New Drugs; 2012 Aug; 30(4):1501-10. PubMed ID: 21567184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]